16 results about "Lung alveolus" patented technology

Disclosed are Schistosoma japonicum eggs and the ingredients of secretions and excretions thereof, comprising eggs, egg culture supernatant, and egg secreted proteins. (hereinafter referred to as “Schistosoma eggs and secretions and excretions thereof” for short). A Schistosoma infection can significantly inhibit metastatic tumors of organs such as lungs, and an anti-tumor effect is mediated by the “Schistosoma eggs and secretions and excretions thereof”, which have the effect of inhibiting various host tumors, comprising lung cancer, liver cancer, melanoma, and hematological tumors. Two egg secreted proteins having an anti-tumor effect are further identified. The “Schistosoma eggs and secretions and excretions thereof” exert an anti-tumor effect by activating natural immunity such as alveolar macrophages. The “Schistosoma eggs and secretions and excretions thereof” have a potential application value in prevention and treatment of tumors in humans.

A method, ventilation system, and ventilation device for assessing lung re-expansion using a controlled ventilation device are disclosed. The method includes: ventilating a subject under first ventilation parameters and acquiring first impedance data; generating a first lung image, wherein each pixel corresponds to one first impedance data; determining a first target region having a preset alveolar opening state based at least on the first impedance data, and obtaining a first evaluation parameter based on the first target region; ventilating the subject under second ventilation parameters for enabling lung re-expansion and acquiring second impedance data; generating a second lung image, wherein each pixel corresponds to one second impedance data; determining a second target region having a preset alveolar opening state based at least on the second impedance data, and obtaining a second evaluation parameter based on the second target region; and obtaining an assessment result of lung re-expansion based on the first and second evaluation parameters. This application achieves an effective assessment of lung re-expansion.

The present invention relates to a composition for inducing the reprogramming of type 1 alveolar cells into type 2 alveolar cells, comprising ML141 as an active ingredient. According to the present invention, by reprogramming AT1 cells into AT2 cells using ML141, it is possible to efficiently secure AT2 cells, which were difficult to obtain in sufficient numbers. Furthermore, it is expected that by reprogramming AT1 cells into AT2 cells within the organoid while culturing the organoid itself rather than culturing a single cell, cells with physiological activity similar to actual tissue can be secured.

This invention discloses the application of a peptide SRD in the preparation of drugs for treating acute lung injury, belonging to the field of biomedical technology. In vivo experiments verified the protective effect of peptide SRD on acute lung injury (ALI), particularly its effect on improving AT2 mitochondrial function. In animal models of ALI, tail vein injection of peptide SRD significantly reduced the protein concentration and total cell count in bronchoalveolar lavage fluid, significantly alleviated the severity of lung injury, lowered histological scores, significantly decreased SOD2 acetylation levels while significantly increasing total SOD2 protein levels, and significantly increased SPC levels (an indicator of AT2 survival). ELISA analysis showed a significant decrease in the levels of IL-6, IL-1β, and TNF-α, indicators of pneumonia in mice. These experimental results confirm that the antioxidant peptide SRD can improve oxidative stress damage in ALI, effectively reduce AT2 cell damage under ALI conditions, promote AT2 regeneration and repair, effectively improve lung function, and reduce the inflammatory response of damaged lungs, thus exhibiting a good therapeutic effect on ALI.

The invention relates to a flow pressure controlled bronchoalveolar lavage tool.

The application discloses a prone position ventilation optimization management system for inhalation injury combined with ARDS, relates to the technical field of medical care information science, and comprises the following steps: acquiring ventilation response parameters, separating airway viscous resistance response components and lung elastic recoil response components, and constructing alveolar ventilation efficiency indexes; based on a sliding time window, the alveolar ventilation efficiency indexes are subjected to change trend and stability analysis, the prone position lung recruitment state is determined, the airway obstruction state is identified in combination with the adjacent breathing cycle change amplitude and change rate, and a comprehensive abnormality determination result is obtained; in the abnormal case, the obstruction type is identified, ventilation and body position coordinated adjustment are performed, the decompression air cushion inflation is adjusted in combination with local pressure monitoring, and closed-loop optimization is realized through review and verification. The problems that, in the prior art, the airway obstruction interference is not effectively eliminated, the ventilation state recognition precision is insufficient, and the adjustment strategy is lagged, thereby limiting the prone position ventilation optimization effect are effectively solved.

This application provides an artificial lung model and its design method. The artificial lung model includes: an air intake assembly with an internal air intake channel; one end of the air intake assembly is connected to one end of a plurality of bronchus and bronchiolar assemblies; the other end of each bronchus and bronchiolar assembly is connected to an artificial alveolar assembly. Each bronchus and bronchiolar assembly includes a tube body, which includes a first connecting section, a second connecting section, and a simulated section located between the first connecting section and the second connecting section; the sum of the internal cavities of all the simulated sections of the tube body is between 50 and 500 mL; the plurality of first connecting sections are all connected to the air intake channel, and the second connecting sections are connected to the artificial alveolar assemblies one by one, so that gas can enter the artificial alveolar assembly from the air intake channel through the tube body.

This invention belongs to the field of targeted drug technology, and specifically relates to the application of PRDX3 protein as a drug target in screening drugs for the prevention and / or treatment of COPD induced by cigarette smoke. This invention demonstrates that the expression level of PRDX3 protein is increased in COPD mouse models and in cigarette smoke-induced MLE-12 alveolar epithelial cells, and also explores the effect of PRDX3 on COPD disease progression. Overexpression of PRDX3 in alveolar epithelial cells significantly improves lung function and lung tissue damage in COPD mice, while knockdown of PRDX3 exacerbates COPD symptoms in COPD mice. This invention provides a novel drug target and candidate compound for the treatment of COPD, and has significant clinical application value.

This invention provides a biomimetic microfluidic device for simulating the three-dimensional structure of alveoli. The fabrication method includes: preparing an inverse opal membrane; bonding the inverse opal membrane to the bottom of a transwell chamber structure (with the bottom filter membrane removed); bonding the top of the transwell chamber to a perforated plate cover; inserting one end of a gas delivery tube through the perforation in the perforated plate cover into the transwell chamber; and connecting the other end to an injection pump; culturing alveolar epithelial cells and vascular endothelial cells on the front and back sides of the inverse opal membrane, respectively, to obtain the biomimetic microfluidic device. The biomimetic microfluidic device provided by this invention can achieve three-dimensional stretching under the action of a microfluidic injection pump, simulating the periodic stretch-recovery process of human lung respiratory movement in vitro. The fabrication method is simple and reliable.

This invention discloses a 3D scaffold for repairing defective lung injury, its construction method, and its applications, belonging to the field of biomedical materials and tissue engineering technology. This invention uses cationic polysaccharide chitosan and polymer γ-polyglutamic acid as raw materials, utilizing their electrostatic interaction to achieve cross-linking without cross-linking agents, and combines this with freeze-drying technology to prepare a three-dimensional spherical γ-PGA / CS composite scaffold. The above composite scaffold is combined with bone marrow stem cell exosomes (MSC-Exos) and type II alveolar epithelial cells (RLE-6TN). By loading exosomes onto the scaffold and implanting lung cells, local enrichment and targeted delivery are achieved, solving the problems of poor targeting of bone marrow stem cell exosomes and easy loss during transplantation of individual cells. This functional scaffold can accelerate lung function recovery by regulating the inflammatory microenvironment at the site of lung injury in SD rats, promoting lung cell regeneration, and reducing secondary lung tissue damage. It provides a novel implantable, minimally invasive treatment for defective lung injury-related diseases, possessing good clinical translational potential and application prospects in organ damage repair.

This invention provides a lung-clearing and cough-relieving herbal remedy, which, based on the total weight percentage of the dried plant materials used to prepare the remedy, comprises the following main components: 8-10% *Corydalis yanhusuo*, 8-10% *Gnaphalium affine*, 8-10% *Citrus reticulata* peel, 7-10% *Houttuynia cordata*, 7-10% *Trichosanthes kirilowii*, 7-9% *Houttuynia cordata*, 7-9% *Polygonum cuspidatum*, 7-9% *Sarcandra glabra*, 6-8% *Adenophora stricta*, 6-8% *Fritillaria cirrhosa*, and 5-7% *Perilla frutescens*. This invention utilizes 11 medicinal herbs... Among the list of items that are both food and medicine, this product is precisely formulated according to the theories of "four qi and five flavors" and meridian tropism. It is rich in natural active ingredients such as fritillary alkaloids, fritillary alkaloid A and B, hesperidin, and houttuynia cordata. It has both dietary and medicinal properties, and is extremely safe. In the first stage, it targets and detoxifies, clears blood vessels and eliminates the root cause of the disease. In the second stage, it reduces inflammation and kills bacteria, repairs damaged alveoli and promotes regeneration. This progressive treatment can not only dissipate pulmonary ground-glass nodules and solid nodules, but also inhibit density transformation and prevent recurrence.

This application relates to the field of biomedical technology, specifically disclosing a siRNA lipid nanoparticle delivery system for treating lung infections, its preparation method, and its application. This application utilizes M2 macrophage-targeting lipid nanoparticles (LNPs) as carriers, delivering WTAP-targeting siRNA to alveolar macrophages via intratracheal instillation. This achieves specific intervention in the m6A methylation modification of alveolar macrophages, thereby actively enhancing the phagocytic clearance, inflammation regulation, and bactericidal functions of AMs, ultimately improving the host's defense against lung bacterial infections (especially drug-resistant bacterial infections).

The application discloses application of a wild chrysanthemum essential oil effective component combination in preparation of a medicine for preventing and treating acute lung injury, and particularly relates to the technical field of biological medicines, wherein the wild chrysanthemum essential oil effective component comprises beta-farnesene, 4-terpenol, artemisia oil, wild chrysanthemum alcohol and carvomenthone, and in an acute lung injury model, the wild chrysanthemum essential oil effective component can significantly regulate the survival state of lung epithelial cells, improve the phenomenon of cell activity decline, and effectively maintain the stability of mitochondrial membrane potential (Delta Psi m). In an acute lung injury mouse model, the wild chrysanthemum essential oil effective component combination can significantly improve the pathological injury of lung tissue, and significantly inhibit the expression of inflammatory mediators in bronchoalveolar lavage fluid (BALF). In summary, the wild chrysanthemum essential oil effective component combination can be applied in preparation of an anti-acute lung injury medicine.

This invention belongs to the field of traditional Chinese medicine (TCM) technology, and particularly relates to a TCM composition, preparation, preparation method, and application. The TCM composition includes areca nut, magnolia bark, cardamom, anemarrhena rhizome, white peony root, scutellaria root, licorice root, honeysuckle flower, forsythia fruit, malt, hawthorn fruit, medicated leaven, and tangerine peel. Experimental results show that after administration of this TCM composition, the IL-10 content in the bronchoalveolar lavage fluid of mice significantly increased; the contents of IL-1β, TNF-α, and IL-6 significantly decreased. This indicates that the TCM composition can reduce lung tissue inflammatory damage by inhibiting the release of pro-inflammatory cytokines IL-1β, TNF-α, and IL-6, and promoting the content of the anti-inflammatory cytokine IL-10. This indicates that the TCM composition has a good therapeutic effect in antiviral inflammatory responses. The drug for antiviral inflammatory responses is a traditional Chinese medicine preparation, safe to use, and the preparation method is simple, rapid, efficient, and easy to operate. The prepared mixtures, granules, pills, tablets, capsules, etc., are easy to carry and convenient to take.

The application discloses a kind of drug combination and its application.The application provides a kind of drug combination or pharmaceutical composition, the active component of the drug combination or pharmaceutical composition includes material A, material B, material C and material D;Material A is compound I or its pharmaceutically acceptable salt;Material B is isoniazid (H) or its pharmaceutically acceptable salt;Material C is rifampicin (R) or its pharmaceutically acceptable salt;Material D is pyrazinamide (Z) or its pharmaceutically acceptable salt.The drug combination or pharmaceutical composition of the application can reduce alveolar inflammation, pulmonary tuberculosis inflammatory lung injury and pulmonary tuberculosis secondary fibrosis, while increasing the penetration of anti-tuberculosis drugs in the lesion site, to accelerate the treatment response, reduce the risk of recurrence.

This invention discloses a simple experimental porcine bronchoalveolar lavage device, comprising a flexible tube with an extension tube connected to its outer side. The other end of the extension tube is connected to a three-way connector. The first outlet of the three-way connector is connected to an endotracheal cannula, and the second outlet is connected to a negative pressure suction device. The other end of the flexible tube is connected to a drip chamber. A flow rate controller A is fitted onto the surface of the flexible tube. The other end of the drip chamber is connected via an adapter to a puncture head assembly A and a puncture head assembly B. Flow rate controller B is located inside the puncture head assembly A and the outside of the drip chamber. This invention, by incorporating modern manufacturing equipment, significantly reduces the complexity of experimental operations, saves time, and improves efficiency. The design and implementation of this device will provide strong support for the construction of acute lung injury models.